(Q33405181)

26 July 2017

1 reference

title

Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma (English)

1 reference

26 July 2017

1 reference

Jennifer L Thompson

1

1 reference

26 July 2017

language of work or name

English

0 references

publication date

8 January 2013

1 reference

Annals of Pharmacotherapy

26 July 2017

published in

1 reference

26 July 2017

volume

47

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

56-62

1 reference

26 July 2017

cites work

Cancer statistics, 2012

1 reference

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

International staging system for multiple myeloma

21 January 2018

1 reference

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma

21 January 2018

1 reference

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

21 January 2018

1 reference

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R561

1 reference

26 July 2017

1 reference